A new study has discovered that these with serious and extended-lasting Covid-19 symptoms are probably to have larger levels of antibody which is required to fight against future infections. This new study from Rutgers University was published in The Journal of Infectious Diseases.
The published paper, ‘Determinants and dynamics of SARS-CoV-2 infection in a diverse population: 6-month evaluation of a prospective cohort study’, was element of the bigger Rutgers Corona Cohort study, which followed some 548 healthcare workers followed by 283 other individuals considering the fact that the starting of the COVID pandemic.
The study discovered that, inside 6 months of the study, out of the total 831 (11 per cent) participants, 93 tested positive for covid-19 or for antibodies. And out of these 93, 24 have been symptomatic and 14 have been asymptomatic to SARS-CoV-2. One-third of the infected participants witnessed symptoms such as fatigue, shortness of breath and loss of taste and smell. These symptoms lasted for at least a month. And 10 per cent had symptoms that lasted for at least 4 months.
Most men and women who have been infected by SARS-CoV-2 created antibodies. The study revealed that antibody production was based on severity of symptoms. 96 per cent of these with serious symptoms have been discovered to have IgG antibodies compared to 89 per cent who had mild to moderate symptoms and 79 per cent who have been asymptomatic.
“Neurological changes, including brain fog and problems with memory or vision, were infrequent among infected participants but did tend to last for many months when they occurred. Notably, having persistent symptoms was also associated with having higher antibody levels over time. We know from other research that vaccination further enhances immune protection and sometimes even helps ease long-term symptoms,” a Rutgers University press release quoted co-lead author Daniel B Horton as saying.
“It is normal for antibody levels to decline over time. Nevertheless, IgG antibodies provide long-term protection to help the body fight reinfection,” Co-lead author Emily S. Barrett was quoted as saying.